Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| Mi | Active Biotech: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING OF ACTIVE BIOTECH AB (PUBL) | 1 | GlobeNewswire (Europe) | |
| The shareholders of Active Biotech AB (publ) are invited to the Extraordinary Shareholders' Meeting to be held on Thursday April 4, 2019, at 5.00 pm in the Company's offices, Scheelevägen 22 in... ► Artikel lesen | ||||
| Mi | Active Biotech has entered into an agreement regarding sale of the Company's property - extraordinary general meeting on April 4, 2019 | 4 | GlobeNewswire (Europe) | |
| Lund Sweden, March 13 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that Active Biotech has entered into an agreement regarding sale of the Company's property Forskaren 1 in Lund... ► Artikel lesen | ||||
| ACTIVE BIOTECH Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| 14.02. | Active Biotech Year-end report January - December 2018 | 1 | GlobeNewswire (Europe) | |
| Fourth quarter in brief
Active Biotech communicated updated information about its financial position
New data from the LEGATO-HD study presented... ► Artikel lesen | ||||
| 11.02. | Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI (durvalumab) in the upcoming Phase 1b/2 study | 11 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN)... ► Artikel lesen | ||||
| 01.02. | Active Biotech has received an indicative bid for the property in Lund - the Board is positive | 6 | GlobeNewswire (Europe) | |
| As previously reported, Active Biotech's property Forskaren 1 in Lund has been on sale for a period of time. Active Biotech has now received an indicative, non-binding bid for the property... ► Artikel lesen | ||||
| 10.12.18 | Active Biotech provides updated information about the company's financial position | 6 | GlobeNewswire (Europe) | |
| PRESS RELEASE
As announced in connection with the interim report for January-September 2018 Active Biotech has requested, from the bank that finances the company's property in Lund, that the... ► Artikel lesen | ||||
| 19.11.18 | Active Biotech's election committee appointed | 3 | GlobeNewswire (Europe) | |
| PRESS RELEASE
In accordance with a decision made by the Annual General Meeting held on May 17, 2018, the Election Committee shall comprise the representatives for the three largest shareholders... ► Artikel lesen | ||||
| 14.11.18 | Active Biotech AB - Interim report January - September 2018 | 7 | GlobeNewswire (Europe) | |
| Third quarter in brief
Active Biotech provides update on laquinimod in Huntington's disease
Active Biotech regains global... ► Artikel lesen | ||||
| 08.11.18 | Active Biotech: New data from the Phase 2 LEGATO-HD study will be presented at HSG 2018 | 3 | GlobeNewswire (Europe) | |
| PRESS RELEASE
New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference HSG 2018
Lund Sweden, November 8,... ► Artikel lesen | ||||
| 13.09.18 | Active Biotech: Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at "European Huntington's Disease Network (EHDN) plenary meeting 2018" | 6 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "European Huntington's Disease Network (EHDN) plenary... ► Artikel lesen | ||||
| 05.09.18 | Active Biotech regains global rights to development and commercialization of laquinimod | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASELund Sweden, September 5, 2018 - Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that it regains the global development and commercialization rights to laquinimod from Teva... ► Artikel lesen | ||||
| 09.08.18 | Active Biotech AB - Interim Report January - June 2018 | 6 | GlobeNewswire (Europe) | |
| Second quarter in brief
The company's... ► Artikel lesen | ||||
| 31.07.18 | Active Biotech provides update on laquinimod in Huntington's disease | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Lund Sweden, July 31, 2018 -Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical... ► Artikel lesen | ||||
| 31.05.18 | Number of shares and votes in Active Biotech | 8 | GlobeNewswire (Europe) | |
| The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 145,236,480 shares... ► Artikel lesen | ||||
| 18.05.18 | Annual General Meeting of Active Biotech AB | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
The Annual General Meeting of Active Biotech was held on May 17, 2018.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be... ► Artikel lesen | ||||
| 17.05.18 | Active Biotech AB Interim report January - March 2018 | 4 | GlobeNewswire (Europe) | |
| First quarter in brief
Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018
Patent... ► Artikel lesen | ||||
| 04.05.18 | Nasdaq Stockholm AB: Delisting of paid subscription shares in Active Biotech AB (62/18) | 3 | GlobeNewswire | |
| The paid subscription shares in Active Biotech AB will be delisted. Last
trading day for ACTI BTA is May 8, 2018.
Instrument: Paid subscription shares
---------------------------------------
Short... ► Artikel lesen | ||||
| 23.04.18 | Annual Report 2017 Active Biotech AB (publ) | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com (http://www.activebiotech.com).
The Annual Report will only be... ► Artikel lesen | ||||
| 18.04.18 | Active Biotech: Notice of Annual General Meeting of Shareholders | 11 | GlobeNewswire (Europe) | |
| The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 17, 2018, at 5 pm at the company's offices, Scheelevägen... ► Artikel lesen | ||||
| 12.04.18 | Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer | 11 | GlobeNewswire (Europe) | |
| PRESS RELEASELund, April 12, 2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| EVOTEC | 21,43 | +1,95 % | Evotec-Aktie: Der nächste Angriff kommt bestimmt! | |
| Im Dezember erfuhr die Evotec-Aktie eine starke Korrektur, doch nach der Jahreswende konnte sie wieder den Vorwärtsgang einlegen und bis zum 11. Januar um gut 20 Prozent auf über 20 Euro ansteigen.... ► Artikel lesen | ||||
| MEDIGENE | 8,735 | +0,98 % | Medigene Aktie: Alarmierender Zustand? | |
| Medigenes Aktie kommt nicht aus der Konsolidierungstendenz heraus, die die vergangenen Tage prägte und eine Abwärtsbewegung von 9,875 Euro auf Freitag erreichte 8,26 Euro brachte. Vom Tiefpunkt dieser... ► Artikel lesen | ||||
| MORPHOSYS | 83,60 | -0,12 % | Leerverkäufer-Alarm! Starke Bewegung bei Steinhoff - deutlicher Aufbau bei Salzgitter AG und MorphoSys sowie Dürr und Aareal Bank - merklicher Abbau bei K+S und Nordex - insgesamt 13 Veränderungen! | |
| Hier finden Sie einen Überblick über die aktuellen Veränderungen bei den Leerverkaufspositionen deutscher Aktien am 15. März Seit geraumer Zeit sind die Aktien deutscher Unternehmen verstärkt ins Visier... ► Artikel lesen | ||||
| BB BIOTECH | 64,70 | +0,39 % | BB Biotech: Eine ganz besondere Dividenden-Spekulation! | |
| Die Aktie des Schweizer Biotech-Investors BB Biotech hat in diesem Jahr bereits einen rasanten Aufstieg hinter sich bringen können. Angetrieben von Übernahmen wie dem Depot-Wert Celgene wie auch weitere... ► Artikel lesen | ||||
| QIAGEN | 35,28 | +0,77 % | Technische Analyse: TecDax startet durch - Qiagen auf neuem Dekadenhoch | |
| (Trendbrief) - Zum Start in die große März-Verfallswoche an den Terminmärkten legten die Aktienmärkte auf breiter Front deutlich zu. Unsere 14 Leitbarometer gewannen im Durchschnitt 1,0% an Wert, wobei... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage